Longevity Health Holdings, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
Longevity Health Holdings, Inc. (XAGE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of -1.00% for the 12-month period ending 2024-12-31, per its 10-K/A filed 2025-06-17.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-06-17
- Longevity Health Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2024 was -1.00%.
- Longevity Health Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2023 was -3.50%.
- Longevity Health Holdings, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2022 was -6.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2024-12-31 | -1.00% 10-K/A · filed 2025-06-17 |
| 2023-12-31 | -3.50% 10-K/A · filed 2025-06-17 |
| 2022-12-31 | -6.40% 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STEPAN CO (SCL) | United States | $1.451B | -477.05 |
| CHURCH & DWIGHT CO INC /DE/ (CHD) | United States | $22.622B | 30.81 |
| ECOLAB INC. (ECL) | United States | $77.183B | 36.58 |
| PROCTER & GAMBLE Co (PG) | United States | $338.763B | 21.26 |